Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
Open Access
- 17 November 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Abstract
Direct-acting antiviral agents (DAAs) provide efficacious therapeutic treatments for chronic Hepatitis C virus (HCV) infection. However, emergence of drug resistance mutations (DRMs) can greatly affect treatment outcomes and impede virological cure. While multiple DRMs have been observed for all currently used DAAs, the evolutionary determinants of such mutations are not currently well understood. Here, by considering DAAs targeting the nonstructural 3 (NS3) protein of HCV, we present results suggesting that epistasis plays an important role in the evolution of DRMs. Employing a sequence-based fitness landscape model whose predictions correlate highly with experimental data, we identify specific DRMs that are associated with strong epistatic interactions, and these are found to be enriched in multiple NS3-specific DAAs. Evolutionary modelling further supports that the identified DRMs involve compensatory mutational interactions that facilitate relatively easy escape from drug-induced selection pressures. Our results indicate that accounting for epistasis is important for designing future HCV NS3-targeting DAAs.Keywords
All Related Versions
This publication has 92 references indexed in Scilit:
- Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor SensitivityAntimicrobial Agents and Chemotherapy, 2012
- Direct-coupling analysis of residue coevolution captures native contacts across many protein familiesProceedings of the National Academy of Sciences of the United States of America, 2011
- Accessory Mutations Maintain Stability in Drug-Resistant HIV-1 ProteaseJournal of Molecular Biology, 2011
- Coordinate linkage of HIV evolution reveals regions of immunological vulnerabilityProceedings of the National Academy of Sciences, 2011
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor bindingProceedings of the National Academy of Sciences, 2010
- Protein Sectors: Evolutionary Units of Three-Dimensional StructureCell, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Identification of direct residue contacts in protein–protein interaction by message passingProceedings of the National Academy of Sciences of the United States of America, 2009
- Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complexProceedings of the National Academy of Sciences, 2008
- Structural and Biological Identification of Residues on the Surface of NS3 Helicase Required for Optimal Replication of the Hepatitis C VirusJournal of Biological Chemistry, 2006